Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.

Frankle WG, Gil R, Hackett E, Mawlawi O, Zea-Ponce Y, Zhu Z, Kochan LD, Cangiano C, Slifstein M, Gorman JM, Laruelle M, Abi-Dargham A.

Psychopharmacology (Berl). 2004 Oct;175(4):473-80.

PMID:
15083259
2.

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.

Pilowsky LS, Busatto GF, Taylor M, Costa DC, Sharma T, Sigmundsson T, Ell PJ, Nohria V, Kerwin RW.

Psychopharmacology (Berl). 1996 Mar;124(1-2):148-53.

PMID:
8935810
3.

Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.

Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BP, van Royen EA.

Psychiatry Res. 1999 Nov 8;92(1):33-44.

PMID:
10688158
4.

Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.

Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinovic S, Kerwin RW, Pilowsky LS.

Psychopharmacology (Berl). 2000 Jun;150(2):132-40.

PMID:
10907666
5.

Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia.

Paquet F, Soucy JP, Stip E, Lévesque M, Elie A, Bédard MA.

J Neuropsychiatry Clin Neurosci. 2004 Winter;16(1):47-56.

PMID:
14990759
6.

Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.

Schmitt GJ, Meisenzahl EM, Dresel S, Tatsch K, Rossmüller B, Frodl T, Preuss UW, Hahn K, Möller HJ.

J Psychopharmacol. 2002 Sep;16(3):200-6.

PMID:
12236625
7.

Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.

Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS.

J Clin Psychopharmacol. 2003 Feb;23(1):5-14.

PMID:
12544369
8.

Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.

Bernardo M, Parellada E, Lomeña F, Catafau AM, Font M, Gómez JC, López-Carrero C, Gutiérrez F, Pavía J, Salamero M.

Psychiatry Res. 2001 Aug 25;107(2):87-97.

PMID:
11530275
9.

In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.

Tauscher J, Küfferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C, Tauscher-Wisniewski S, Brücke T, Kasper S.

Psychopharmacology (Berl). 1999 Jan;141(2):175-81.

PMID:
9952042
10.
11.

Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.

Dresel S, Tatsch K, Dähne I, Mager T, Scherer J, Hahn K.

J Nucl Med. 1998 Jul;39(7):1138-42.

12.

Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia.

de Haan L, Booij J, Lavalaye J, van Amelsvoort T, Linszen D.

Psychopharmacology (Berl). 2006 Jan;183(4):500-5. Epub 2005 Nov 15.

PMID:
16292589
13.

In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.

Dresel S, Mager T, Rossmüller B, Meisenzahl E, Hahn K, Möller HJ, Tatsch K.

Eur J Nucl Med. 1999 Aug;26(8):862-8.

PMID:
10436199
14.

[123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.

Klemm E, Grünwald F, Kasper S, Menzel C, Broich K, Danos P, Reichmann K, Krappel C, Rieker O, Briele B, Hotze AL, Möller HJ, Biersack HJ.

Am J Psychiatry. 1996 Feb;153(2):183-90.

PMID:
8561197
15.

D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.

Meisenzahl EM, Dresel S, Frodl T, Schmitt GJ, Preuss UW, Rossmüller B, Tatsch K, Mager T, Hahn K, Möller HJ.

J Psychopharmacol. 2000;14(4):364-70.

PMID:
11198054
16.

Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.

de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J.

Am J Psychiatry. 2000 Jun;157(6):1019-20.

PMID:
10831489
17.

Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.

Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC.

JAMA Psychiatry. 2015 Sep;72(9):927-34. doi: 10.1001/jamapsychiatry.2015.0891.

PMID:
26131622
18.

In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine.

Raedler TJ, Knable MB, Lafargue T, Urbina RA, Egan MF, Pickar D, Weinberger DR.

Psychiatry Res. 1999 Apr 26;90(2):81-90.

PMID:
10482380
19.

Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study.

Kasper S, Tauscher J, Küfferle B, Barnas C, Hesselmann B, Asenbaum S, Podreka I, Brücke T.

Psychopharmacology (Berl). 1998 Apr;136(4):367-73.

PMID:
9600582
20.

Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol.

Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY.

Neuropsychopharmacology. 2005 Dec;30(12):2283-9.

Supplemental Content

Support Center